Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | GRN | P28799 | 2/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656866 | 0.92 | LMNA (0.45) | OPRM1OPRD1LMNALIPEGRN | |
| SCHEMBL21656977 | 0.88 | LMNA (0.57) | OPRM1OPRD1LMNALIPEGRN | |
| SCHEMBL21656972 | 0.88 | MAPT (0.48) | OPRM1OPRD1LMNALIPEGRN | |
| SCHEMBL21656587 | 0.88 | HPGD (0.58) | LMNAHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL21656859 | 0.87 | OPRM1 (0.49) | OPRM1OPRD1LMNAOPRK1 | |
| SCHEMBL23228796 | 0.85 | LMNA (0.42) | LMNALIPEHPGDSMN1; SMN2HRH3 | |
| SCHEMBL21656983 | 0.85 | PDE4B (0.50) | LMNALIPETSHR | |
| SCHEMBL21628553 | 0.82 | OPRM1 (0.54) | OPRM1OPRD1LMNALIPEHPGD | |
| SCHEMBL23228824 | 0.82 | HPGD (0.38) | LMNAHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL20953495 | 0.78 | KDM4E (0.59) | LMNALIPEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | OPRM1 4075/4885OPRD1 3247/4885LMNA 3083/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | OPRM1 3978/4885OPRD1 2899/4885LMNA 3327/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | OPRM1 3978/4885OPRD1 2899/4885LMNA 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.